Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced it has dosed the first patient in its Phase 1 clinical trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE